Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.

Cancer medicine - 1 May 2023

Gao Fan, Hu Kai, Zheng Peihao, Shi Hui, Ke Xiaoyan

Abstract excerpt

BACKGROUND: TP53 mutations have a prognostic significance in relapsed and refractory diffuse large B-cell lymphoma (rrDLBCL) patients, and their treatment still faces a great challenge. This study aimed to evaluate the prognosis of patients with TP53 mutations (TP53mut) in the context of CAR-T therapy (Chimeric antigen receptor T-cell therapy) as well as explore the heterogeneity in their cohort and identify the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to DEAD-box RNA Helicases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma Diagnosis and Treatment

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Prognosis

Share to Receptors, Chimeric Antigen

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 36971051
DOI: 10.1002/cam4.5756
PMCID: PMC10225230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.PMID 36971051Read ↗

TP53 mutation and immunohistochemical p53 expression characteristics in diffuse large B–cell lymphomaSemantic proximity Read ↗

Prognostic Analysis of Diffuse Large B-Cell Lymphoma Patients Based on Clinical Characteristics, TP53 Mutation Status, and Number of Co-mutated GenesSemantic proximity Read ↗

Prognostic Impact of TP53 Mutations in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

[Clinical characteristics and prognostic analysis of diffuse large B-cell lymphoma with TP53 mutation].Semantic proximity Read ↗

Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targetsSemantic proximity Read ↗

TP53 mutations predict poor prognosis in diffuse large B-cell lymphoma: A single-center studySemantic proximity Read ↗

Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms.Semantic proximity Read ↗

Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL.Semantic proximity Read ↗

Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.Semantic proximity Read ↗

Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer LandscapesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.